natgillin/translations-raw huggingface dataset:
On the first day of treatment, start with Leganto 2 mg (package marked “Week 1”), and use one Leganto 2 mg transdermal patch daily. 
Prvi dan zdravljenja začnite z zdravilom Leganto 2 mg (pakiranje označeno z nalepko “1.
Do not take the following medicines while using Leganto - because they may decrease its effect: 
Naslednjih zdravil ne jemljite med uporabo zdravila Leganto, saj lahko zmanjšajo njegov učineko:
At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine versus placebo 25%, CI95% 13%; 36%, difference pramipexole versus placebo 32%, CI95% 21%; 43%, difference pramipexole versus rotigotine 7%, CI95% -2%; 17%). 
Na koncu vzdrževalnega zdravljenja so opazili vsaj 30-odstotno izboljšanje pri 60 % bolnikov, ki so prejemali rotigotin, pri 67 % bolnikov, ki so prejemali pramipeksol, in pri 35 % bolnikov, ki so prejemali placebo (razlika med rotigotinom in placebom je bila 25 %; CI95% 13 % - 36 %, razlika med pramipeksolom in placebom je bila 32 %; CI95% 21 % - 43 %, razlika med pramipeksolom in rotigotinom je bila 7 %; CI95% -2 % - 17 %).
At the beginning of the third week, you should take Leganto 6 mg (package marked with “Week 3”). 
Na začetku tretjega tedna zdravljenja uporabite zdravilo Leganto 6 mg (pakiranje označeno z nalepko“3.
Because rotigotine enters your bloodstream through your skin, food or drink does not affect the way this medicine is absorbed by the body. 
Zdravilo Leganto skupaj s hrano, pijačo in alkoholom Rotigotin vstopa v krvni obtok skozi kožo, zato hrana in pijača na absorpcijo zdravila v telo ne vplivata.
Adverse reactions of increased creatine phosphokinase (CPK) were observed with rotigotine in clinical studies conducted in Japan. 
Pri kliničnih študijah, izvedenih na Japonskem, so opazili neželene učinke zvišane kreatin fosfokinaze (CPK).
• constipation, dry mouth, heartburn 
• zaprtje, suha usta, zgaga
paranoia e, confusional state e, psychotic disorder e, delusion e, delirium e 
psihotične motnje e, blodnje e, delirij e
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e. 8 mg/24 h. An improvement of 20% was seen in 52% of the subjects receiving rotigotine, 68% of the subjects receiving ropinirole and 30% of the subjects receiving placebo (Difference rotigotine versus placebo 21.7%, CI95% 11.1%; 32.4%, difference ropinirole versus placebo 38.4%, CI95% 28.1%; 48.6%, difference ropinirole versus rotigotine 16.6%, CI95% 7.6%; 25.7%). 
Na koncu vzdrževalnega zdravljenja je bil optimalni odmerek pri 92 % bolnikov, ki so prejemali rotigotin, največji dovoljeni odmerek, tj. 8 mg/24 h. 20-odstotno izboljšanje so opazili pri 52 % bolnikov, ki so prejemali rotigotin, 68 % bolnikov, ki so prejemali ropinirol, in pri 30 % bolnikov, ki so prejemali placebo (razlika med rotigotinom in placebom je bila 21,7 %; CI95% 11,1 % - 32,4 %; razlika med ropinirolom in placebom je bila 38,4 %, CI95% 28,1 %- 48,6 %; razlika med ropinirolom in rotigotinom je bila 16,6 %, CI95% 7,6 % - 25,7 %).
AST, ALT, GGT), weight increased, heart rate increased, CPK increased d 
(vključno z AST, ALT, γ GT), povečanje telesne mase e, pospešeno bitje srca e, zvišan CPK
• Thigh or hip. 
• stegno ali kolk.
Plasma levels of conjugates of rotigotine and its desalkyl metabolites increase with impaired renal function. 
Ravni konjugatov rotigotina in njegovih presnovkov po dealkilaciji v plazmi se pri okvarjenem delovanju ledvic povečajo, vendar ni vpliva teh presnovkov na klinične učinke
A dose reduction might be needed in case of worsening of the hepatic impairment. 
Če se jetrna okvara poslabša, bo mogoče potrebno zmanjšanje odmerka.
• vertigo (sensation of whirling motion) 
• vrtoglavica (občutek vrtenja)
Constipation e, 
zmedenost e,
• if you have serious liver problems, your doctor may need to change the dose. 
• vam bo moral zdravnik prilagoditi odmerek, če imate resne težave z jetri.
Leganto 2 mg/24 h Leganto 4 mg/24 h Leganto 6 mg/24 h Leganto 8 mg/24 h Transdermal patch 
Leganto 2 mg/24 h Leganto 4 mg/24 h Leganto 6 mg/24 h Leganto 8 mg/24 h Transdermalni obliž rotigotin
Each patch of 30 cm contains 13.5 mg of rotigotine. 
Vsak obliž s površino 30 cm vsebuje 13,5 mg rotigotina.
CGI-I responder rates (much improved, very much improved) were 43.0% and 67.5% for placebo and rotigotine respectively (difference 24.5% CI 95%: 14.2%; 34.8%, p<0.0001). 
Stopnje odziva po CGI-1 (precej izboljšan, zelo izboljšan) so bile 43,0 % za placebo in 67,5% za rotigotin (razlika 24,5% CI95%: 14,2 % - 34,8 %, p<0,0001) V 7-tedenskem, s placebom nadzorovanem preskušanju so bili raziskani polisomnografski parametri.
• abnormal heart beat 
• nenormalen srčni ritem
If your doctor says you should stop Leganto, the daily dose should be lowered gradually: 
Če se zdravnik odloči za prenehanje zdravljenja z zdravilom Leganto, je treba dnevni odmerek zdravila Leganto morate zmanjševati postopoma:
What Leganto is Leganto contains the active substance rotigotine. 
Kaj je zdravilo Leganto Zdravilo Leganto vsebuje učinkovino rotigotin.
• skin irritations under the patch such as redness and itching 
• draženje kože pod obližem, kot sta rdečica in srbenje
Side effects when using Leganto for Restless Legs Syndrome Tell your doctor or pharmacist if you notice any of the following side effects: 
Neželeni učinki pri uporabi zdravila Leganto za zdravljenje sindroma nemirnih nog Če se pojavijo naslednji neželeni učinki se posvetujte z zdravnikom ali farmacevtom:
Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. 
Pri nekaterih bolnikih, ki so zdravljeni z dopaminergičnimi snovmi, pridelanimi iz ergota, so poročali o primerih retroperitonealne fibroze, pljučnih infiltratov, plevralnega izliva, plevralne odebelitve, perikarditisa in srčne valvulopatije.
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p<0.001 for both rotigotine groups). 
Na koncu vzdrževalnega zdravljenja so opazili vsaj 30-odstotno izboljšanje pri 57 % bolnikov, ki so prejemali 8 mg rotigotina/24 h, pri 55 % bolnikov, ki so prejemali 12 mg rotigotina/24 h, in pri 34 % bolnikov, ki so prejemali placebo (pri skupini, ki je prejemala 8 mg rotigotina/24 h, je bila razlika 22 %; CI95% 10 % - 35 %, pri skupini, ki je prejemala 12 mg rotigotina/24 h, pa 21 %; CI95% 8 % - 33 %, p<0,001 pri obeh skupinah, ki sta prejemali rotigotin).
Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, Povidone K90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and 
Samolepilna matriksna plast poli(dimetilsiloksan, trimetilsililsilikat)-kopolimerizat, povidon K90, natrijev metabisulfit (E223), askorbilpalmitat (E304) in
If you still get problems with your skin because of the patch, please see ‘Skin problems caused by the patch' in section 4 for more information. 
Če imate zaradi obliža še vedno težave s kožo, si za dodatne informacije poglejte ‘Kožne reakcije, povzročene z obližem' v poglavju 4.
The mean reduction in the “off” time was 2.5 hours in the rotigotine arm, 2.8 hours in the pramipexole arm and 0.9 hours in the placebo arm. All differences between the active treatments and placebo were statistically significant. 
Srednja vrednost zmanjšanja časa »izklop« je bila pri skupini, ki je prejemala rotigotin, 2,5 ure, pri skupini, ki je prejemala pramipeksol, 2,8 ure, pri skupini, ki je prejemala placebo, pa 0,9 ure.
Observed in studies performed in patients with Parkinson's disease Description of selected adverse reactions 
Opaženo pri študijah z bolniki s Parkinsonovo boleznijo Opis izbranih neželenih učinkov Nenaden spanec in somnolenca
Augmentation may occur. 
Pojavi se lahko avgmentacija.
For example the daily dose of 10 mg may be reached by applying one patch of 6 mg/24 h and one patch of 4 mg/24 h. 
Na primer dnevni odmerek 10 mg lahko dosežete tako, da uporabite en obliž z odmerkom 6 mg/24 h in enega z odmerkom 4 mg/24 h.
At the beginning of the second week, you should take Leganto 4 mg (package marked with “Week 2”). 
Na začetku drugega tedna zdravljenja uporabite zdravilo Leganto 4 mg (pakiranje označeno z nalepko “2.
• Press the patch down firmly with the palm of your hand. 
• Obliž z dlanjo močno pritisnite.
Erythema e, hyperhidrosis e, 
Bolezni kože in podkožja pruritus eritem e, hiperhidroza e,
Then, the patch is fold back and the second part of the release liner is removed. 
Nato obliž prepognemo nazaj in odstranimo še drugo polovico zaščitne plasti.
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine (see section 4.4). 
Pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom, se lahko pojavi patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje (glejte poglavje 4.4).
Leganto may make you feel very sleepy and you may fall asleep very suddenly. 
Vpliv na sposobnost upravljanja vozil in strojev Zaradi zdravila Leganto ste lahko zelo zaspani in lahko povsem nenadno zaspite.
• The maximum dose is 8 mg each day. 
• Največji dnevni odmerek je 8 mg.
The outside is tan-coloured and is imprinted with Leganto 1 mg/24 h or 3 mg/24 h. 
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 1 mg/24 h ali 3 mg/24 h.
• Make sure that you take the old patch off before putting on a new one. 
• Preden nalepite nov obliž, se prepričajte, da ste odstranili stari obliž.
BOX OF 7 PATCHES - WEEK 1 
ŠKATLA S 7 OBLIŽI - 1.
Leganto may decrease blood pressure when you stand up 
Zdravilo Leganto lahko zniža krvni tlak, ko vstanete - ta učinek se lahko poslabša ob jemanju zdravila za zniževanje krvnega tlaka.
Ophthalmologic monitoring 
Okulistični nadzor
• Keep it pressed for about 
• Pritiskajte približno 30
Each patch of 15 cm contains 6.75 mg of rotigotine. 
Vsak obliž s površino 15 cm vsebuje 6,75 mg rotigotina.
hallucination, hallucination visual, hallucination auditory, illusion), insomnia, sleep disorder, nightmare, abnormal dreams, impulsecontrol disorders a,d 
(halucinacije, vizualne halucinacije, zvočne halucinacije, iluzije), nespečnost, motnje spanja, nočne more, nenavadne sanje, motnje pri kontroli dražljajev a,d napadi spanca/nenaden spanec, paranoja, motnje spolnega poželenja a
Aggressive behaviour/ aggression b, disorientation d 
obsesivno kompulzivna motnja, agitiranost d nasilno vedenje/ agresivnost b, dezorientiranost d dopaminski disregulacijski sindrom c,
Each patch of 40 cm contains 18.0 mg of rotigotine. 
Vsak obliž s površino 40 cm vsebuje 18,0 mg rotigotina.
Peel apart the foil. 
Odstranite folijo.
• Peel off one side of the release liner. 
• Odstranite eno stran zaščitne plasti.
fatigue, asthenia, malaise) 
(vključno z utrujenostjo, astenijo, splošnim slabim počutjem)
dermatitis contact e, rash generalised e 
kontaktni dermatitis e,
• 8 mg/24 h: Each patch releases 8 mg of rotigotine per 24 hours. 
• 8 mg/24 h: Vsak obliž sprosti 8 mg rotigotina v 24 urah.
BOX OF 7 PATCHES - WEEK 4 
ŠKATLA S 7 OBLIŽI - 4.
6.1 List of excipients 
6.1 Seznam pomožnih snovi Oporna plast
Each patch of 5 cm contains 2.25 mg of rotigotine. 
En obliž s površino 5 cm2 vsebuje 2,25 mg rotigotina.
dizziness postural e, lethargy e, convulsion e 
posturalna omotica e, letargija e,
The primary outcome assessment was the score for the Activities of Daily Living (ADL) component (Part II) plus the Motor Examination component (Part III) of the Unified Parkinson's Disease Rating Scale (UPDRS). 
Ocena primarne končne točke raziskave je bila rezultat komponente dnevnih aktivnosti (ADL) (II.
erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity), asthenic conditions a 
(vključno z eritemom, pruritusom, draženjem, izpuščajem, dermatitisom, mehurji, bolečino, ekcemom, vnetjem, oteklino, razbarvanjem, papulami, lupljenjem, koprivnico, preobčutljivostjo), astenična stanja a
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 16 mg/24 h over 8 weeks, followed by a maintenance period of 4 weeks. 
8 tednov so bolnikom odmerek postopno povečevali do optimalnega odmerka rotigotina ali placeba v tedenskih korakih po 2 mg/24 h, od 2 mg/24 h do največjega odmerka 16 mg/24 h, nato so 4 tedne prejemali vzdrževalni odmerek.
Respiratory, thoracic and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora kolcanje
erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity) 
(vključno z eritemom, pruritusom, draženjem, izpuščajem, dermatitisom, mehurji, bolečino, ekcemom, vnetjem, oteklino, razbarvanjem, papulami, lupljenjem, koprivnico, preobčutljivostjo)
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 6 mg/24 h. Patients in each treatment group were maintained at their optimal dose for 6 months. 
Bolnikom so odmerek postopno povečevali do optimalnega odmerka rotigotina ali placeba v tedenskih korakih po 2 mg/24 h, od 2 mg/24 h do največjega odmerka 6 mg/24 h. Bolniki v vseh skupinah so svoj optimalni odmerek prejemali 6 mesecev.
• loss of consciousness, involuntary movements (dyskinesia) 
• izguba zavesti, nehoteni gibi (diskinezija)
Hypertension Orthostatic hypotension 
Žilne bolezni hipertenzija ortostatska hipotenzija hipotenzija e
The patients were titrated to their optimal doses of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 4 mg/24 h. Patients in each treatment group were maintained at their optimal dose for 6 months. 
Bolnikom so odmerek postopno povečevali do optimalnega odmerka rotigotina ali placeba v tedenskih korakih po 2 mg/24 h, z začetnim odmerkom 4 mg/24 h. Bolniki v vseh skupinah so svoj optimalni odmerek prejemali 6 mesecev.
BOX OF 7 PATCHES - WEEK 3 
ŠKATLA S 7 OBLIŽI - 3.
The outside is tan-coloured and is imprinted with Leganto 4 mg/24 h Leganto 6 mg/24 h or Leganto 8 mg/24 h. 
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 4 mg/24 h, Leganto 6 mg/24 h ali Leganto 8 mg/24 h.
Leganto 8 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 8 mg/24 h'. 
Leganto 8 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 8 mg/24 h'.
Each patch of 20 cm contains 9.0 mg of rotigotine. 
Vsak obliž s površino 20 cm vsebuje 9,0 mg rotigotina.
Skin adhesion was measured on 2 consecutive days of 24 hours patch application. 
Uporabljeni so bili obliži z rotigotinom 8 mg/24 h. Oprijem na koži so merili 2 zaporedna dneva z uporabo vsakega obliža 24 ur.
Dopaminergic adverse reactions 
Dopaminergični neželeni učinki
7 transdermal patches of Leganto 6 mg/24 h 
7 transdermalnih obližev Leganto 6 mg/24 h
7 transdermal patches of Leganto 8 mg/24 h 
7 transdermalnih obližev Leganto 8 mg/24 h
BOX OF 7 PATCHES - WEEK 2 
ŠKATLA S 7 OBLIŽI - 2.
The patch should be applied to clean, dry, intact healthy skin on the abdomen, thigh, hip, flank, shoulder, or upper arm. Reapplication to the same site within 14 days should be avoided. 
Obliž namestimo na čisto, suho, nepoškodovano zdravo kožo na trebuhu, stegnih, kolkih, bokih, ramah ali nadlahteh.
Put the patch in the original sachet and then throw it away safely, out of the reach of children. 
Po odstranitvi je treba obliž prepogniti na pol, z lepljivo plastjo navznoter, ga dati v originalno zaščitno vrečko in nato odstraniti tako, da je zunaj dosega otrok.
Transdermal use. 
transdermalni obliž
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h'. 
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali 8 mg/24 h'.
7 transdermal patches of Leganto 4 mg/24 h 
7 transdermalnih obližev Leganto 4 mg/24 h
Nausea, vomiting Constipation, dry mouth, dyspepsia 
Bolezni prebavil navzea, bruhanje zaprtje, suha usta, dispepsija bolečine v trebuhu driska c
• swelling of legs and feet 
• otekanje nog in stopal
How to store Leganto 
Shranjevanje zdravila Leganto
• feeling dizzy 
• bruhanje, zgaga
Leganto 8 mg/24 h transdermal patch EU/1/11/695/046 
Leganto 8 mg/24 h transdermalni obliž EU/1/11/695/046
1 transdermal patch 
1 transdermalni obliž
• 3 mg/24 h: Each patch releases 3 mg of rotigotine per 24 hours. 
• 3 mg/24 h: Vsak obliž sprosti 3 mg rotigotina v 24 urah.
• falling 
• padci
• Each patch releases 2 mg of rotigotine per 24 hours. 
• Vsak obliž sprosti 2 mg rotigotina v 24 urah.
• 6 mg/24 h: Each patch releases 6 mg of rotigotine per 24 hours. 
• 6 mg/24 h: Vsak obliž sprosti 6 mg rotigotina v 24 urah.
In both cases, use a new patch at the usual time on the following day. 
V obeh primerih zamenjajte obliž z novim ob običajnem času naslednji dan. Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Each patch of 10 cm contains 4.5 mg of rotigotine. 
En obliž s površino 10 cm2 vsebuje 4,5 mg rotigotina.
Leganto 8 mg/24 h transdermal patch Each patch releases 8 mg of rotigotine per 24 hours. 
Leganto 8 mg/24 h transdermalni obliž En obliž sprosti 8 mg rotigotina v 24 urah.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 2 mg/24 h'. 
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 2 mg/24 h'.
Leganto 1 mg/24 h transdermal patch EU/1/11/695/001 
Leganto 1 mg/24 h transdermalni obliž EU/1/11/695/001
• diarrhoea 
• blodnje
Leganto 6 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 6 mg/24 h'. 
Leganto 6 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 6 mg/24 h'.
• feeling weak (fatigue) 
• občutek šibkosti (izčrpanost)
Each patch releases 1 mg of rotigotine per 24 hours. 
Vsak obliž sprosti 1 mg rotigotina v 24 urah.
System/organ classes acc. to MedDRA 
Organski sistem po MedDRA
• Talk to your doctor if you have a skin reaction that lasts longer than a few days or is severe. 
• Če imate kožno reakcijo, ki traja dlje kot nekaj dni ali je huda ali se razširi zunaj mesta, ki ga je pokrival obliž, se posvetujte z zdravnikom.
dry mouth e, abdominal pain e, diarrhoea c 
Bolezni dihal, prsnega koša in mediastinalne ga prostora kolcanje e
The outside is tan-coloured and is imprinted with Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h. 
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali 8 mg/24 h.
Each patch releases 8 mg of rotigotine per 24 hours. 
En obliž sprosti 8 mg rotigotina v 24 urah.
This is because 
Na primer,
Leganto 4 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 4 mg/24 h'. 
Leganto 4 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 4 mg/24 h'.
Dizziness e, disturbances in consciousness NEC 
Bolezni živčevja glavobol somnolenca omotica e, motnje zavesti NEC
Leganto 6 mg/24 h transdermal patch EU/1/11/695/037 
Leganto 6 mg/24 h transdermalni obliž EU/1/11/695/037
syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy 
(vključno s sinkopo, vazovagalno sinkopo, izgubo zavesti) diskinezija, posturalna omotica, letargija konvulzija sindrom padajoče glave c
• From the second week, your daily dose may be increased by 1 mg each week - until you get to the right maintenance dose for you. 
• Od drugega tedna dalje se vam lahko dnevni odmerek zvišuje po 1 mg vsak teden - dokler se ne bo dosegel za vas ustrezen vzdrževalni odmerek.
Leganto 1 mg/24 h transdermal patch Leganto 3 mg/24 h transdermal patch 
Leganto 1 mg/24 h transdermalni obliž Leganto 3 mg/24 h transdermalni obliž
Tell your doctor if you notice any changes in behaviour, thinking or both that are listed above. 
Povejte svojemu zdravniku, če se pri vas pojavijo kakršne koli spremembe v vedenju, mišljenju ali obeh, kot je navedeno zgoraj.
• From the second week your daily dose may be increased by 2 mg each week - until you get to the right maintenance dose for you. 
• Od drugega tedna dalje se vam lahko dnevni odmerek zvišuje po 2 mg vsak teden - dokler se ne bo dosegel za vas ustrezen vzdrževalni odmerek.
Each patch releases 6 mg of rotigotine per 24 hours. 
En obliž sprosti 6 mg rotigotina v 24 urah.
B. PACKAGE LEAFLET 
• zamegljen vid
With rotigotine, the mean reductions in “off” time were 2.7 and 2.1 hours, respectively whereas in the placebo-treated arm a reduction of 0.9 hours was observed. 
Pri rotigotinu je bila srednja vrednost zmanjšanja časa »izklop« 2,7 ure pri skupini, ki je prejemala 8 mg rotigotina/24 h, in 2,1 ure pri skupini, ki je prejemala 12 mg rotigotina/24 h. Pri skupini, ki je prejemala placebo, je bilo zmanjšanje 0,9 ure.
190 patients received rotigotine, and 97 placebo. 
81,5 % bolnikov se je sočasno zdravilo z L-dopo.190 bolnikov je prejemalo rotigotin in 97 placebo.
Leganto 3 mg/24 h transdermal patch EU/1/11/695/019 
Leganto 3 mg/24 h transdermalni obliž EU/1/11/695/019
Augmentation may occur in Restless Legs Syndrome patients. 
Pri bolnikih s sindromom nemirnih nog se lahko pojavi avgmentacija.
Leganto 6 mg/24 h transdermal patch Each patch releases 6 mg of rotigotine per 24 hours. 
Leganto 6 mg/24 h transdermalni obliž En obliž sprosti 6 mg rotigotina v 24 urah.
Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. 
Pri nenadni prekinitvi dopaminergičnega zdravljenja so poročali o simptomih, ki kažejo na maligni nevroleptični sindrom.
Leganto 4 mg/24 h transdermal patch Each patch releases 4 mg of rotigotine per 24 hours. 
Leganto 4 mg/24 h transdermalni obliž En obliž sprosti 4 mg rotigotina v 24 urah.
7 transdermal patches. 
7 transdermalnih obližev 2. teden
EU/1/11/695/046 [7 transdermal patches] EU/1/11/695/048 [28 transdermal patches] EU/1/11/695/049 [30 transdermal patches] 
EU/1/11/695/046 [7 transdermalnih obližev] EU/1/11/695/048 [28 transdermalnih obližev] EU/1/11/695/049 [30 transdermalnih obližev]
SACHET LABEL - WEEK 1 
7 transdermalnih obližev 1. teden
Weight decreased e, hepatic enzyme increased e 
Poškodbe in zastrupitve padci a
• feeling sleepy or dizzy 
• občutek zaspanosti ali omotice
Leganto is available in different strength patches which release the medicine over 24 hours.The strengths are 1 mg/24 h, 2 mg/24 h and 3 mg/24 h for the treatment of Restless Leg Syndrome. 
Jakosti 1 mg/24 h, 2 mg/24 h in 3 mg/24 h so za zdravljenje sindroma nemirnih nog.
The outside is tan-coloured and is imprinted with Leganto 2 mg/24 h. 
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 2 mg/24 h.
Leganto 3 mg/24 h transdermal patch Each patch releases 3 mg of rotigotine per 24 hours. 
Leganto 3 mg/24 h transdermalni obliž En obliž sprosti 3 mg rotigotina v 24 urah.
EU/1/11/695/019 [7 transdermal patches] EU/1/11/695/021 [28 transdermal patches] EU/1/11/695/022 [30 transdermal patches] 
EU/1/11/695/019 [7 transdermalnih obližev] EU/1/11/695/021 [28 transdermalnih obližev] EU/1/11/695/022 [30 transdermalnih obližev]
EU/1/11/695/001 [7 transdermal patches] EU/1/11/695/003 [28 transdermal patches] EU/1/11/695/004 [30 transdermal patches] 
EU/1/11/695/001 [7 transdermalnih obližev] EU/1/11/695/003 [28 transdermalnih obližev] EU/1/11/695/004 [30 transdermalnih obližev]